Printer Friendly

COMPANY INFORMATION
Orbus Pharma Inc. 20 Konrad Cres Markham, ON L3R 8T4 Tel: (905) 943-9444 Fax: (905) 943-9878 Contact Name Greg W. Muir Industry Pharmaceuticals		Key Executives Andrew B. Zaleski, interim CEO Greg W. Muir, CFO Develops and manufactures generic oral dose drugs, which are the therapeutic equivalent to their brand name counterparts. The drugs are licensed to sales and marketing organizations primarily in Europe and Canada followed by the U.S., which distributes them in their respective markets under their own name.
FP ADVISOR COVERAGE Orbus Pharma Inc. • FP Corporate Surveys • FP Directory of Directors • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Pharmaceuticals Company Name Revenue ($000s)  Biovail Corporation 807,909 Patheon Inc. 765,812 Cangene Corporation 238,751 Dragon Pharmaceutical, Inc. 162,127 Paladin Labs Inc. 82,744 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/ORB.H $0.03 $0.22 $0.01 n.a. n.a. n.a. 3.92 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 192,684 n.a. $-0.11 Sept. 30/09 25.0% -58.9% -50.83% $1,524
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Operating revenue 839 1,491 2,782 Net income (8,775) (6,792) (5,688) Total assets 9,792 14,429 12,942 $ $ $ Earnings per share* (0.14) (0.14) (0.14) % % % Return on equity n.m. (107.65) (96.05)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 $000s $000s Operating revenue 766 1,061 Net income (7,167) (7,296) $ $ Earnings per share (0.12) (0.12)

COMPANY NEWS

Results for 'Orbus Pharma Inc.' from past 30 days: No hits. (Links are to articles.)